School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Pharmacy and Bank Building A15, NSW 2006, Australia.
Division of Engineering, New York University Abu Dhabi, Abu Dhabi, Saadiyat Campus, P.O. Box 129188, United Arab Emirates.
Adv Drug Deliv Rev. 2024 Nov;214:115456. doi: 10.1016/j.addr.2024.115456. Epub 2024 Sep 19.
The ability of three-dimensional (3D) bioprinting to fabricate biomimetic organ and disease models has been recognised to be promising for drug discovery and development as 3D bioprinted models can better mimic human physiology compared to two-dimensional (2D) cultures and animal models. This is useful for target selection where disease models can be studied to understand disease pathophysiology and identify disease-linked compounds. Lead identification and preclinical studies also benefit from 3D bioprinting as 3D bioprinted models can be utilised in high-throughput screening (HTS) systems and to produce efficacy and safety data that closely resembles clinical observations. Although no published applications of 3D bioprinting in clinical trials were found, there are two clinical trials planning to evaluate the predictive ability of 3D bioprinted models by comparing human and model responses to the same chemotherapy. Overall, this review provides a comprehensive summary of the latest applications of 3D bioprinting in drug discovery and development.
三维（3D）生物打印技术能够制造仿生器官和疾病模型，这对于药物发现和开发具有广阔的前景，因为与二维（2D）培养物和动物模型相比，3D 生物打印模型可以更好地模拟人体生理学。这对于靶点选择非常有用，因为可以通过疾病模型来研究疾病的病理生理学并确定与疾病相关的化合物。先导化合物的鉴定和临床前研究也受益于 3D 生物打印，因为 3D 生物打印模型可以用于高通量筛选（HTS）系统，并生成与临床观察非常相似的疗效和安全性数据。尽管没有发现 3D 生物打印在临床试验中的已发表应用，但有两项临床试验计划通过比较人类和模型对同种化疗药物的反应来评估 3D 生物打印模型的预测能力。总的来说，本综述全面总结了 3D 生物打印在药物发现和开发中的最新应用。
